Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 180

1.

Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials.

Reich K, Leonardi C, Langley RG, Warren RB, Bachelez H, Romiti R, Ohtsuki M, Xu W, Acharya N, Solotkin K, Colombel JF, Hardin DS.

J Am Acad Dermatol. 2017 Mar;76(3):441-448.e2. doi: 10.1016/j.jaad.2016.10.027. Epub 2016 Dec 24. Erratum in: J Am Acad Dermatol. 2017 Aug;77(2):390-390.e1.

2.

Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data.

Strober B, Leonardi C, Papp KA, Mrowietz U, Ohtsuki M, Bissonnette R, Ferris LK, Paul C, Lebwohl M, Braun DK, Mallbris L, Wilhelm S, Xu W, Ljungberg A, Acharya N, Reich K.

J Am Acad Dermatol. 2017 Mar;76(3):432-440.e17. doi: 10.1016/j.jaad.2016.09.026. Epub 2016 Nov 23.

3.

Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease.

Hohenberger M, Cardwell LA, Oussedik E, Feldman SR.

J Dermatolog Treat. 2018 Feb;29(1):13-18. doi: 10.1080/09546634.2017.1329511. Epub 2017 May 31. Review.

PMID:
28521565
4.

Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis.

Papp KA, Bachelez H, Blauvelt A, Winthrop KL, Romiti R, Ohtsuki M, Acharya N, Braun DK, Mallbris L, Zhao F, Xu W, Walls CD, Strober B.

Br J Dermatol. 2017 Dec;177(6):1537-1551. doi: 10.1111/bjd.15723. Epub 2017 Nov 16.

PMID:
28600810
6.

A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis.

Gordon KB, Leonardi CL, Lebwohl M, Blauvelt A, Cameron GS, Braun D, Erickson J, Heffernan M.

J Am Acad Dermatol. 2014 Dec;71(6):1176-82. doi: 10.1016/j.jaad.2014.07.048. Epub 2014 Sep 19.

PMID:
25242558
7.

Incidence of Crohn's Disease and Ulcerative Colitis in Rhode Island: Report from the Ocean State Crohn's and Colitis Area Registry.

Shapiro JM, Zoega H, Shah SA, Bright RM, Mallette M, Moniz H, Grabert SA, Bancroft B, Merrick M, Flowers NT, Samad Z, Lidofsky S, LeLeiko NS, Sands BE.

Inflamm Bowel Dis. 2016 Jun;22(6):1456-61. doi: 10.1097/MIB.0000000000000745.

8.

Isotretinoin and risk for inflammatory bowel disease: a nested case-control study and meta-analysis of published and unpublished data.

Etminan M, Bird ST, Delaney JA, Bressler B, Brophy JM.

JAMA Dermatol. 2013 Feb;149(2):216-20. doi: 10.1001/jamadermatol.2013.1344.

PMID:
23426479
9.

[Incidence of inflammatory bowel diseases in Bretagne (1994-1995). ABERMAD. Association Bertonne d'Etude et de Recherche des Maladies de l'Appareil Digesif].

Pagenault M, Tron I, Alexandre JL, Cruchant E, Dabadie A, Chaperon J, Robaszkiewicz M, Bretagne JF.

Gastroenterol Clin Biol. 1997;21(6-7):483-90. French.

10.

The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled Phase 3 studies of patients with moderate-to-severe plaque psoriasis.

Reich K, Puig L, Mallbris L, Zhang L, Osuntokun O, Leonardi C.

J Eur Acad Dermatol Venereol. 2017 Jul;31(7):1196-1207. doi: 10.1111/jdv.14252. Epub 2017 May 4.

PMID:
28370467
11.

Occurrence of adverse events among patients with inflammatory bowel disease in the HealthCore Integrated Research Database.

McAuliffe ME, Lanes S, Leach T, Parikh A, Faich G, Porter J, Holick C, Esposito D, Zhao Y, Fox I.

Curr Med Res Opin. 2015;31(9):1655-64. doi: 10.1185/03007995.2015.1065242. Epub 2015 Aug 20.

PMID:
26135040
12.

Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials.

Langley RG, Kimball AB, Nak H, Xu W, Pangallo B, Osuntokun OO, Agada N, Reich K.

J Eur Acad Dermatol Venereol. 2019 Feb;33(2):333-339. doi: 10.1111/jdv.15242. Epub 2018 Nov 22.

PMID:
30198588
13.

Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies.

Gottlieb AB, Lacour JP, Korman N, Wilhelm S, Dutronc Y, Schacht A, Erickson J, Zhang L, Mallbris L, Gerdes S.

J Eur Acad Dermatol Venereol. 2017 Apr;31(4):679-685. doi: 10.1111/jdv.13990. Epub 2016 Nov 2.

14.

Inflammatory bowel disease: A descriptive study of 716 local Chilean patients.

Simian D, Fluxá D, Flores L, Lubascher J, Ibáñez P, Figueroa C, Kronberg U, Acuña R, Moreno M, Quera R.

World J Gastroenterol. 2016 Jun 14;22(22):5267-75. doi: 10.3748/wjg.v22.i22.5267.

15.

Fistulizing pattern in Crohn's disease and pancolitis in ulcerative colitis are independent risk factors for cancer: a single-center cohort study.

Biancone L, Zuzzi S, Ranieri M, Petruzziello C, Calabrese E, Onali S, Ascolani M, Zorzi F, Condino G, Iacobelli S, Pallone F.

J Crohns Colitis. 2012 Jun;6(5):578-87. doi: 10.1016/j.crohns.2011.11.005. Epub 2011 Dec 20.

PMID:
22398047
16.

Incidence and phenotype at diagnosis of inflammatory bowel disease. Results in Spain of the EpiCom study.

Fernández A, Hernández V, Martínez-Ares D, Sanromán L, de Castro ML, Pineda JR, Carmona A, González-Portela C, Salgado C, Martínez-Cadilla J, Pereira S, García-Burriel JI, Vázquez S, Rodríguez-Prada I; EpiCom Group.

Gastroenterol Hepatol. 2015 Nov;38(9):534-40. doi: 10.1016/j.gastrohep.2015.03.001. Epub 2015 Apr 15.

PMID:
25890448
17.

Epidemiological and clinical characteristics of inflammatory bowel diseases in Cairo, Egypt.

Esmat S, El Nady M, Elfekki M, Elsherif Y, Naga M.

World J Gastroenterol. 2014 Jan 21;20(3):814-21. doi: 10.3748/wjg.v20.i3.814.

18.

Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.

Chatzinasiou F, Polymeros D, Panagiotou M, Theodoropoulos K, Rigopoulos D.

Acta Dermatovenerol Croat. 2016 Apr;24(1):83-5.

PMID:
27149138
19.

Clinical characteristics of inflammatory bowel disease in Turkey: a multicenter epidemiologic survey.

Tozun N, Atug O, Imeryuz N, Hamzaoglu HO, Tiftikci A, Parlak E, Dagli U, Ulker A, Hulagu S, Akpinar H, Tuncer C, Suleymanlar I, Ovunc O, Hilmioglu F, Aslan S, Turkdogan K, Bahcecioglu HI, Yurdaydin C; Members of the Turkish IBD Study Group.

J Clin Gastroenterol. 2009 Jan;43(1):51-7. doi: 10.1097/MCG.0b013e3181574636.

PMID:
18724251
20.

Decreasing incidence of inflammatory bowel disease in eastern Canada: a population database study.

Leddin D, Tamim H, Levy AR.

BMC Gastroenterol. 2014 Aug 9;14:140. doi: 10.1186/1471-230X-14-140.

Supplemental Content

Support Center